General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Dymista (azelastine/fluticasone propionate)
Status:
Negotiations were not pursued
Manufacturer:
Meda Pharmaceuticals
Indication:
Seasonal allergic rhinitis
Last updated July 24, 2015
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated July 22, 2015
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Thromboembolic events (venous), treatment and prevention of recurrence
Last updated July 9, 2015
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated July 2, 2015
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Last updated June 30, 2015
Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C
Last updated June 16, 2015
Abilify Maintena (aripiprazole)
Status:
Concluded with an LOI
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Schizophrenia
Last updated June 14, 2015
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Last updated June 2, 2015
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Thrombocytopenia associated with chronic hepatitis c infection
Last updated May 28, 2015
Status:
Negotiations were not pursued
Manufacturer:
Aegerion Pharmaceuticals Canada Ltd.
Indication:
Homozygous Familial Hypercholesterolemia
Last updated May 26, 2015